Zilretta
Zilretta Now Available for Osteoarthritis Knee Pain
December 01, 2017Flexion Therapeutics announced the availability of Zilretta (triamcinolone acetonide extended-release injectable suspension) indicated for the management of pain associated with osteoarthritis (OA) of the knee.
FDA Approves Zilretta NDA for Knee Osteoarthritis
February 16, 2017The Food and Drug Administration has accepted for review the New Drug Application for Zilretta for the treatment of patients with osteoarthritis of the knee.
Clinical Pain Advisor Articles
- Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
- Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis
- Tackling the Chronic Pain and Opioid Use Disorder Crises Through Public-Private Partnerships
- How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics
- Pain Tolerance in Buprenorphine Maintenance Treatment
- Radiofrequency Ablation for Chronic Hip Pain: Reviewing the Evidence
- Opioid Use Disorder Treatment: Evidence-Based Guideline
- Betel Quid Addiction and Implications for Substance Use Disorder
- Low Back Pain: Contributing Factors, Prophylactic Strategies, and Effective Treatments
- Peripherally Acting Opioid and Cannabinoid May Be Effective for Neuropathic Pain
- Transcranial Magnetic Stimulation May Prevent Migraine in Adolescents
- Widespread Impact of Reducing Opioids, Adding IV Acetaminophen for Postsurgical Pain Management
- GI Safety Compared for NSAIDs in Patients With Arthritis
- Opioid Prescribing Trends in Patients With, Without Cancer
- DOJ Rescinds Protections Afforded by Americans With Disabilities Act
\